Squamous Cell Carcinoma of Head and Neck and Immune System
Authors:
J. Bouček 1; S. Partlová 1,3; K. Kloudová 2,3; M. Zábrodský 1; R. Špíšek 2,3; A. Fialová 2,3
Authors‘ workplace:
Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN v Motole, Praha
1; Ústav imunologie 2. LF UK a FN v Motole, Praha
2; Sotio, Praha
3
Published in:
Otorinolaryngol Foniatr, 62, 2016, No. 4, pp. 221-223.
Category:
Review Article
Overview
Squamous cell carcinoma of head and neck still belongs to the diseases with very uncertain prognosis. Effectivity of the treatment remains approximately the same during the recent years despite the considerable progress in therapeutic methods and increasing level of knowledge about the biology of the tumor cells in relation with the host. Oropharyngeal cancers associated with the human papillomavirus (HPV) infection are different in clinical manifestation, course and prognosis. One may speculate that this fact can be explained by the distinction of the immune system. The main characteristics of immune response of HPV associated tumors and cancers with the different etiology are summarized in the text.
Keywords:
squamous cell carcinoma of head and neck, immune systém, T-lymphocytes, tumor microenvironment, HPV
Sources
1. Badoual, C., Hans, S., Merillon, N. et al.: PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res., 73, 2013, 1, s. 128-138.
2. Boucek, J., Mrkvan, T., Chovanec, M. et al.: Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J. Cell Mol. Med., 141, 2010, 1-2, s.426-43.
3. Brahmer, J., Reckamp, K.L., Baas, P. et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med., 373, 2015, 2, s. 123-135.
4. Cojoc, M., Peitzsch, C., Trautmann, F. et al.: Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther, 2013, 6, s. 1347-1361.
5. Hamid, O., Robert, C., Daud, A. et al.: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med., 369, 2013, 2, s. 134-144.
6. Klozar, J., Kratochvil, V., Salakova, M. et al.: HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch. Otorhinolaryngol., 265, 2008, Suppl 1, s. S75-82.
7. Koslabova, E., Hamsikova, E., Salakova, M. et al.: Markers of HPV infection and survival in patients with head and neck tumors. Int. J. Cancer, 133, 2013, 8, s. 1832-1839.
8. Le, D. T., Uram, J. N., Wang, H. et al.: PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med., 372, 2015, 26, s. 2509-2520.
9. Lukesova, E., Boucek, J., Rotnaglova, E. et al.: High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. Biomed. Res. Int., 201,. s. 303-929.
10. Partlova, S., Boucek, J., Kloudova, K. et al.: Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology, 4, 2015, 1, s. e965570.
11. Schumacher, T. N., Schreiber, R. D.: Neoantigens in cancer immunotherapy. Science, 348, 2015, s. 69-74.
12. Spanos, W. C., Nowicki, P., Lee, D. W. et al.: Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch. Otolaryngol. Head Neck Surg,, 135, 2009, 11, s. 1137-1146.
13. Tachezy, R., Klozar J., Salačova M. et al.: HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. Oral Dis, 11, 2005, 3, s. 181-185.
14. Vojtechova, Z., Sabol I., Salačova M. et al.: Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients‘ prognosis. Int. J. Cancer, 138, 2016, 2, s. 386-395.
Labels
Audiology Paediatric ENT ENT (Otorhinolaryngology)Article was published in
Otorhinolaryngology and Phoniatrics
2016 Issue 4
Most read in this issue
- Antromastoidectomy in Childhood
- Papillary Thyroid Carcinoma: Analysis of the Size of the Primary Tumor, Infiltration of the Thyroid Capsule and Lymfangioinvasiona Due to Metastatic Involvment of Regional Lymph Nodes and Age
- Surgical Management of Ménière’s Disease: Our Experience with Endolymphatic Sac Decompression
- Presbycusis